Literature DB >> 21963602

Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.

Xiaojian Wang1, Hongmei Li, Catherine Matte-Martone, Weiguo Cui, Ning Li, Hung Sheng Tan, Derry Roopenian, Warren D Shlomchik.   

Abstract

Recipient antigen-presenting cells (APCs) initiate GVHD by directly presenting host minor histocompatibility antigens (miHAs) to donor CD8 cells. However, later after transplantation, host APCs are replaced by donor APCs, and if pathogenic CD8 cells continue to require APC stimulation, then donor APCs must cross-present host miHAs. Consistent with this, CD8-mediated GVHD is reduced when donor APCs are MHC class I(-). To study cross-presentation, we used hosts that express defined MHC class I K(b)-restricted miHAs, crossed to K(b)-deficient backgrounds, such that these antigens cannot be directly presented. Cross-priming was surprisingly efficient, whether antigen was restricted to the hematopoietic or nonhematopoietic compartments. Cross-primed CD8 cells were cytolytic and produced IFN-γ. CD8 cells were exclusively primed by donor CD11c(+) cells, and optimal cross-priming required that they are stimulated by both type I IFNs and CD40L. In studying which donor APCs acquire host miHAs, we made the surprising discovery that there was a large-scale transfer of transmembrane proteins from irradiated hosts, including MHC class I-peptide complexes, to donor cells, including dendritic cells. Donor dendritic cells that acquired host MHC class I-peptide complexes were potent stimulators of peptide-specific T cells. These studies identify new therapeutic targets for GVHD treatment and a novel mechanism whereby donor APCs prime host-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963602      PMCID: PMC3236124          DOI: 10.1182/blood-2011-06-358747

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  TCR-Mediated internalization of peptide-MHC complexes acquired by T cells.

Authors:  J F Huang; Y Yang; H Sepulveda; W Shi; I Hwang; P A Peterson; M R Jackson; J Sprent; Z Cai
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

2.  Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner.

Authors:  D Hudrisier; J Riond; H Mazarguil; J E Gairin; E Joly
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

3.  Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes.

Authors:  Clotilde Théry; Livine Duban; Elodie Segura; Philippe Véron; Olivier Lantz; Sebastian Amigorena
Journal:  Nat Immunol       Date:  2002-11-11       Impact factor: 25.606

4.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

5.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

6.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon.

Authors:  Agnes Le Bon; Nathalie Etchart; Cornelia Rossmann; Miranda Ashton; Sam Hou; Dirk Gewert; Persephone Borrow; David F Tough
Journal:  Nat Immunol       Date:  2003-09-21       Impact factor: 25.606

7.  Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide.

Authors:  Eun Young Choi; Gregory J Christianson; Yoshitaka Yoshimura; Thomas J Sproule; Nadja Jung; Sebastian Joyce; Derry C Roopenian
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

8.  Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others.

Authors:  E Y Choi; Y Yoshimura; G J Christianson; T J Sproule; S Malarkannan; N Shastri; S Joyce; D C Roopenian
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

9.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.

Authors:  A Cerwenka; A B Bakker; T McClanahan; J Wagner; J Wu; J H Phillips; L L Lanier
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

10.  Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease.

Authors:  Eun Young Choi; Gregory J Christianson; Yoshitaka Yoshimura; Nadja Jung; Thomas J Sproule; Subramaniam Malarkannan; Sebastian Joyce; Derry C Roopenian
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

View more
  21 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 2.  Autophagy and haematopoietic stem cell transplantation.

Authors:  Lucie Leveque; Laetitia Le Texier; Katie E Lineburg; Geoffrey R Hill; Kelli P A MacDonald
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

Review 3.  Biology of graft-versus-host responses: recent insights.

Authors:  Kelli P MacDonald; Warren D Shlomchik; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2013-01       Impact factor: 5.742

4.  In vivo dynamics of T cells and their interactions with dendritic cells in mouse cutaneous graft-versus-host disease.

Authors:  Sarah Morin-Zorman; Christian Wysocki; Jieqing Zhu; Hongmei Li; Sylvain Zorman; Catherine Matte-Martone; Edwina Kisanga; Jennifer McNiff; Dhanpat Jain; David Gonzalez; David M Rothstein; Fadi G Lakkis; Ann Haberman; Warren D Shlomchik
Journal:  Blood Adv       Date:  2019-07-23

Review 5.  Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer.

Authors:  Furong Zeng; Adrian E Morelli
Journal:  Semin Immunopathol       Date:  2018-03-28       Impact factor: 9.623

6.  Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Authors:  T A Seldon; R Pryor; A Palkova; M L Jones; N D Verma; M Findova; K Braet; Y Sheng; Y Fan; E Y Zhou; J D Marks; T Munro; S M Mahler; R T Barnard; P D Fromm; P A Silveira; Z Elgundi; X Ju; G J Clark; K F Bradstock; D J Munster; D N J Hart
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

7.  Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.

Authors:  Barbara Érsek; Nikolett Lupsa; Péter Pócza; Anett Tóth; Andor Horváth; Viktor Molnár; Bence Bagita; András Bencsik; Hargita Hegyesi; András Matolcsy; Edit I Buzás; Zoltán Pós
Journal:  Cell Mol Life Sci       Date:  2016-04-30       Impact factor: 9.261

Review 8.  The biology of graft-versus-host disease: experimental systems instructing clinical practice.

Authors:  Kate A Markey; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

9.  Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Authors:  Amin M Alousi; Jennifer Le-Rademacher; Rima M Saliba; Frederick R Appelbaum; Andrew Artz; Jonathan Benjamin; Steven M Devine; Fangyu Kan; Mary J Laughlin; Hillard M Lazarus; Jane Liesveld; Miguel-Angel Perales; Richard T Maziarz; Mitchell Sabloff; Edmund K Waller; Mary Eapen; Richard E Champlin
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

Review 10.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.